Recombinant glycoprotein vaccines for human immunodeficiency virus-infected children and their effects on viral quasispecies

Clin Diagn Lab Immunol. 2002 Jan;9(1):79-82. doi: 10.1128/cdli.9.1.79-82.2002.


In individuals infected with human immunodeficiency virus type 1 (HIV-1), specific immunity is associated with a more diverse viral repertoire and slower disease progression. Attempts to enhance antiviral immunity with therapeutic vaccination have shown that recombinant glycoprotein (RGP) vaccines are safe, well tolerated, and immunogenic, but the effect of RGP vaccines on the viral repertoire is unknown. We evaluated diversification of the viral envelope in 12 HIV-infected children who received placebo or RGP vaccines. At baseline, 11 of 12 patients had multiple viral variants. On follow-up 6 months later, children who had a strong vaccine-associated lymphoproliferative immune response showed less viral diversification than those in whom the immune response was weak or absent. These results suggest that the immune response elicited by RGP vaccines does not exert a significant selection pressure on the viral quasispecies and therefore may not be helpful in changing the course of the disease.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • AIDS Vaccines / immunology*
  • Acquired Immunodeficiency Syndrome / immunology*
  • Acquired Immunodeficiency Syndrome / virology
  • Child
  • Child, Preschool
  • HIV / classification*
  • HIV Envelope Protein gp120 / immunology*
  • HIV Envelope Protein gp160 / immunology*
  • HIV-1 / immunology*
  • Humans
  • Infant
  • Lymphocyte Activation
  • Vaccination
  • Vaccines, Synthetic / immunology*


  • AIDS Vaccines
  • HIV Envelope Protein gp120
  • HIV Envelope Protein gp160
  • Vaccines, Synthetic